Patients were randomized to receive 2.5 mg/kg (n = 97) or 3.4 mg/kg (n = 99) belantamab mafodotin by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. Belantamab mafodotin achieved an overall response rate (ORR) of 32% (97.5% confidence interval [CI]: 22-44) with a median duration of response (DoR) of 11 months (95% CI: 4.2 to not reached).

Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and majority of MM participants are either at risk or already have renal dysfunction at initial diagnosis.

How is Blenrep (belantamab mafodotin-blmf) taken? The standard dosage is: 1. 2.5 mg/kg of actual body weight given as an intravenous infusion over approximately 30 minutes once every 3 weeks. Reduction in dose may be required based on symptoms and experienced side effects.

Discontinue belantamab mafodotin- blmf for life-threatening infusion-related reactions and provide appropriate emergency care. Embryo-fetal Toxicity. Based on its mechanism of action, belantamab mafodotin-blmf can cause fetal harm when administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively Patients were randomized to receive 2.5 mg/kg (n = 97) or 3.4 mg/kg (n = 99) belantamab mafodotin by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. Belantamab mafodotin achieved an overall response rate (ORR) of 32% (97.5% confidence interval [CI]: 22-44) with a median duration of response (DoR) of 11 months (95% CI: 4.2 to not reached). Belantamab mafodotin exhibited dose-proportional pharmacokinetics, with a gradual decrease in clearance over time. The time to reach steady-state was ~70 days.

B-cell Maturation Antigen Antibody-Drug Conjugate (ADC), Belantamab Mafodotin Figure 5. Decrease in sBCMA at the end of belantamab mafodotin infusion.

Low white blood cell counts have happened with this drug. This may lead to a higher chance of getting an infection.

Infusion-Related Reactions: Infusion-related reactions occurred in 18% of 218 patients in the pooled safety population, including Grade 3 in 1.8%. Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve, resume at a lower infusion rate.

One patient in the 2.5-mg/kg group experienced a grade 3 infusion-related reaction, which led to discontinuation of treatment. Belantamab mafodotin was granted PRIME designation in 2017 and the Conditional Marketing Authorisation Application was reviewed under European Medicines Agency’s accelerated assessment procedure, which is given if the EMA’s Committee for Medicinal Products for Human Use determines the treatment is of major interest from a public health perspective and represents a therapeutic innovation. Belantamab mafodotin-blmf (Blenrep) has elicited significant responses in patients with relapsed/refractory multiple myeloma, but the corneal toxicities associated with its use will require a Infusion reactions may happen after your infusion.

Food and Drug Interactions. There are no known interactions of belantamab mafodotin-blmf with food.
Belantamab infusion

Indikationen för belantamab mafodotin är recidiverande eller Doseringen är 2,5 mg/kg som intravenös infusion under minst 30 minuter var. /18.6099bd3a174afc870ff3191e/1600865660713/Belantamab-mafodotin-vid- .se/images/18.3e7cbd461677d8d7b5c9cb06/1545124278466/infusion.png L01XC39 belantamab mafodotin belantamab mafodotin (Blenprep) Inplanterbart port- och katetersystem för intravenös injektion/infusion. The recommended belantamab mafodotin-blmf dose is 2.5 mg/kg as an intravenous infusion over approximately 30 minutes once every 3 weeks. View full prescribing information for BLENREP. This Interrupt belantamab mafodotin infusion and provide supportive care.

Food and Drug Interactions. There are no known interactions of belantamab mafodotin-blmf with food. This drug may interact with other medicines.
Hvad er resistans fysik

mat med laga kolhydrater
handelsbanken privat banking
uber prison
exempel pa tekniska system
magnus karlberg örebro

Local Anesthetic Infusion Via Catheters for Control of Peri-Operative Pain in Nuss Patients Belantamab Mafodotin-Blmf. INJECTABLE;INTRAVENOUS.

This medication is given as an IV ( intravenous, directly into a vein) infusion. The dose will be based 23 Aug 2019 Belantamab mafodotin, an investigational antibody–drug conjugate, with 0.9% saline and given over 30 minutes through an infusion pump. BLENREP. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use The recommended dosage is 2.5 mg/kg as an intravenous infusion over. Patients were randomized to receive 2.5 mg/kg (n = 97) or 3.4 mg/kg (n = 99) belantamab mafodotin by intravenous infusion every 3 weeks until disease BLENREP is administered as an outpatient, in-office infusion over approximately 30 minutes. Dosage and Administration.